# GOVX — Geovax Labs Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** GOVX  
**Sources:** 23  
**Published:** 2026-11-01  
**Canonical:** https://app.k3vl4r.com/research/deep-research-govx-geovax-labs-inc-catalysts-narrative-risks-10540

---

## Company Snapshot

GeoVax Labs, Inc. (Nasdaq: GOVX) is a clinical-stage biotechnology company headquartered in Atlanta, Georgia, developing vaccines and immunotherapies for high-consequence infectious diseases and solid-tumor cancers using a Modified Vaccinia Ankara (MVA) vector / virus-like particle (VLP) platform [[15]](https://biopharmsignal.com/company/GOVX), [[18]](https://www.marketbeat.com/stocks/NASDAQ/GOVX/), [[26]](https://en.wikipedia.org/wiki/GeoVax). Its lead program is GEO-MVA (an MVA-based mpox/smallpox vaccine), alongside Gedeptin (an oncology gene-therapy candidate) [[14]](https://biotechreporter.news/geovax-labs-nasdaqgovx-announces-pivotal-phase-3-trial-for-geo-mva-vaccine/), [[15]](https://biopharmsignal.com/company/GOVX). The company was formed in 2001 and trades on the Nasdaq Capital Market (a sector classification consistent with "Healthcare") [[18]](https://www.marketbeat.com/stocks/NASDAQ/GOVX/), [[26]](https://en.wikipedia.org/wiki/GeoVax).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-govx-geovax-labs-inc-catalysts-narrative-risks-10540 (free to sign up)._